



Kansas City

An Independent Licensee of the Blue Cross and Blue Shield Association

Nutrient/Nutritional Panel Testing

Policy Number: 2.04.136

Last Review: 10/2018

Origination: 10/2015

Next Review: 10/2019

Policy

Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for Nutrient/Nutritional Panel Testing. This is considered investigational.

If the test or procedure **is not** listed in the member's list of benefits, and Blue Cross and Blue Shield of Kansas City determines that it was done on an individual without specific symptoms of a condition or disease for which the test was done, it will be considered a non-covered screening test.

Note: This is a type of testing that may be excluded in some contracts. Verify benefits prior to review for Medical Necessity.

When Policy Topic is covered

n/a

When Policy Topic is not covered

Nutrient/nutritional panel testing is considered **investigational** for all indications including but not limited to testing for nutritional deficiencies in patients with mood disorders, fibromyalgia, unexplained fatigue and healthy individuals.

Description of Procedure or Service

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> • With mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals seeking to optimize health and sports fitness 	Interventions of interest are: <ul style="list-style-type: none"> • Nutritional panel testing 	Comparators of interest are: <ul style="list-style-type: none"> • Standard care 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Change in disease status • Functional outcomes

Multimarker nutritional panel testing is proposed for patients with certain chronic conditions (eg, mood disorders, fibromyalgia, unexplained fatigue) as well as for healthy individuals seeking to optimize health and/or fitness.

For individuals who have mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals who seek to optimize health and fitness who receive nutritional panel testing, the evidence includes several systematic reviews on the association

between a single condition and a single nutrient and on the treatment of specific conditions with nutritional supplements. Relevant outcomes are symptoms, change in disease status, and functional outcomes. There was no evidence of associations between fibromyalgia or unexplained fatigue and nutrient deficiencies. Systematic reviews have found statistically significant associations between depression and levels of several nutrients; however, there is no evidence that nutrient supplementation for patients with depression improves health outcomes. Also, there is no direct evidence on the health benefits of nutritional panel testing for any condition, including testing healthy individuals, and no evidence that nutritional panel testing is superior to testing for individual nutrients for any condition. The evidence is insufficient to determine the effects of the technology on health outcomes.

Background

Nutritional panel testing aims to identify nutritional deficiencies that will lead to personalized nutritional supplement recommendations. Testing is proposed both for healthy individuals to optimize health and for patients with chronic conditions (eg, mood disorders, fibromyalgia, chronic fatigue) to specify supplements that will ameliorate symptoms.

Genova Diagnostics offers nutritional/nutrient panel testing. Among tests this company offers is NutrEval FMV, which involves analysis of urine and blood samples and provides information on more than 100 markers including organic acids, amino acids, fatty acids, markers of oxidative stress (direct measurement of glutathione and CoQ10, and markers of oxidative injury and DNA damage) and nutrient elements (see Table 1).¹

Genova Diagnostics produces a report that includes test results categorized as normal, borderline, and high need, along with recommendations for supplements and dosages for items categorized as high need. NutrEval FMV patient reports can recommend supplementation or any of the nutrients listed in Table 1 if they are found to be areas of high need.

A related test, the ONE (Optimal Nutritional Evaluation) FMV also by Genova Diagnostics, limits testing to the organic acid, amino acid, and oxidative stress marker categories.

SpectraCell Laboratories offers a micronutrient test that measures functional deficiencies at the cellular level. The test assesses how well the body uses 33 vitamins, minerals, amino and fatty acids, antioxidants, and metabolites (see Table 1). SpectraCell categorizes test results into adequate, borderline, and deficient, and offers supplementation suggestions based on each patient's deficiencies.

Table 1. Components of the NutrEval FMV Test

Category	NutrEval	SpectraCell Nutrient Testing
B vitamins	Thiamin B ₁ , riboflavin B ₂ , niacin B ₃ , pyridoxine B ₆ , biotin B ₇ , folic acid	Vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , vitamin B ₆ , vitamin B ₁₂ ,

	B ₉ , cobalamin B ₁₂	biotin, folate, pantothenate, vitamin C, vitamin D, vitamin K
Minerals	Magnesium, manganese, molybdenum, zinc	Calcium, magnesium, manganese, zinc, copper
Fatty acids	Omega-3-oils	Oleic acid
Digestive support	Probiotics, pancreatic enzymes	
Other vitamins	Vitamin D	
Amino acids	Arginine, asparagine, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, taurine, threonine, tryptophan, tyrosine, valine	Asparagine, glutamine, serine

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments.

Nutrient/nutritional panel testing using urine and/or blood samples is offered (eg, NutrEval FMV® and ONE FMV® by Genova Diagnostics; micronutrient testing by SpectraCell) under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Rationale

This evidence review was created in August 2015 and has been updated regularly with searches of the MEDLINE database. The most recent literature update was performed through November 7, 2017.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Direct evidence that nutrient/nutritional panel testing improves health outcomes would consist of randomized controlled trials that compare outcomes in patients managed with and without nutrient/nutritional panel testing. In the absence of direct evidence, a chain of evidence can be examined. Nutrient/nutritional panel

tests are specifically targeted at patients with mood disorders, fibromyalgia, and chronic fatigue so that this review will focus on those conditions. The following is a summary of the key literature.

NUTRIENT/Nutritional PANEL TESTING

Clinical Context and Test Purpose

The purpose of nutrient/nutritional panel testing in patients who have mood disorders, fibromyalgia, or unexplained fatigue or in healthy individuals seeking to optimize health and fitness is to inform a decision whether the patient might benefit from specific nutrient supplementation.

The question addressed in this evidence review is: Does nutrient/nutritional panel testing, to identify nutrient deficiencies, result in improved health outcomes among patients with mood disorders, fibromyalgia, or unexplained fatigue or among healthy individuals seeking to optimize health and fitness compared with standard of care.

The following PICOTS were used to select literature to inform this review.

Patients

The relevant populations of interest are patients with mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals seeking to optimize health and fitness.

Interventions

The relevant intervention of interest is nutrient/nutritional panel testing.

Comparators

The relevant comparator of interest is standard of care.

Outcomes

The potential beneficial outcomes of primary interest would be an improvement in symptoms, change in disease status, and functional outcomes. The potential harmful outcomes are those resulting from a false test result. False-positive or false-negative test results can lead to the initiation of unnecessary treatment and adverse events from that overtreatment or undertreatment.

Timing

Nutrient/nutritional panel testing might be conducted before or after starting specific therapy for the specific conditions addressed herein or as a screening test for healthy individuals seeking to optimize health and fitness.

Setting

Ordering and interpreting nutrient/nutritional panel testing should be done by physicians in an outpatient or inpatient setting.

Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

Clinically Valid

Evidence to support the clinical validity of nutrient/nutritional panel testing would require studies that report the sensitivity, specificity, and positive and negative predictive values of these tests in detecting nutritional deficiency compared with a criterion standard test, preferably among the study population of interest. Currently, there is no literature reporting on the clinical validity of nutrient/nutritional panel tests in this target population.

Clinically Useful

The chain of evidence to support the clinical utility of the use of nutrient/nutritional panel testing would consist of: (1) evidence that specific nutritional deficiencies included in the panel test are significantly associated with mood disorders, fibromyalgia, and/or chronic fatigue; (2) evidence that, in patients with mood disorders, fibromyalgia, and/or chronic fatigue, treatment of a patient found to have specific nutritional deficiencies (eg, with nutritional supplements) improves health outcomes; and (3) evidence that, if there is sufficient evidence on the first 2 items, panel testing is more appropriate than testing for specific nutrients.

No studies were identified that directly evaluated the impact of nutrient/nutritional panel testing on health outcomes. Evidence for a chain of evidence is examined next.

Mood Disorders, Fibromyalgia, or Unexplained Fatigue

Several systematic reviews and meta-analyses evaluating associations between the indications of interest and specific nutrient deficiencies were identified, and they are described in Table 2. No systematic reviews or meta-analyses were identified on the association between nutritional deficiencies and unexplained fatigue. A limitation of all reviews is that, although they compared low and high levels of nutrient levels, none addressed whether these low levels constituted actual deficiencies in a particular nutrient.

Table 2. Systematic Reviews on the Association Between Nutritional Deficiencies and Mood Disorders, Fibromyalgia, and Unexplained Fatigue

Study	Nutrient	No. of Studies	Specified Cutoff for Nutrient Deficiency	Key Findings
Depression				
Swardfager et al (2013)²	Zinc	17	No	Mean serum zinc concentrations of -1.85 µmol/L (95% CI, -2.52 to -1.19 µmol/L) in depressed patients vs

Study	Nutrient	No. of Studies	Specified Cutoff for Nutrient Deficiency	Key Findings
Anglin et al (2013)³	Vitamin D	14	No	<p>nondepressed controls ($p < 0.001$)</p> <p>Cross-sectional studies:</p> <ul style="list-style-type: none"> OR of depression, highest vs lowest vitamin D categories: 1.31 (95% CI, 1.00 to 1.71; $p = 0.03$) <p>Prospective series:</p> <ul style="list-style-type: none"> Risk of developing depression significantly higher in patients with lower vitamin D (HR=2.21; 95% CI, 1.40 to 3.49; $p = 0.028$)
Petridou et al (2015)⁴	Folate and vitamin B ₁₂	11	No	<p>Odds of having depression significantly associated with low folate and vitamin B levels:</p> <ul style="list-style-type: none"> Folate: OR=1.27 (95% CI, 1.07 to 1.43) Vitamin B: OR=1.20 (95% CI, 1.02 to 1.42)
Cheungpasitporn et al (2015)⁵	Magnesium	6	No	<p>Pooled RR of depression in patients with hypomagnesemia (3 cohort studies, 2 cross-sectional studies, 1 case-control study combined; N=19,137 patients):</p> <ul style="list-style-type: none"> 1.34 (95% CI, 1.01 to 1.79; $I^2 = 33\%$) <p>Pooled RR excluding the cross-sectional studies:</p> <ul style="list-style-type: none"> 1.38 (95% CI, 0.92 to 2.07; $I^2 = 24\%$)
Fibromyalgia				
Daniel and Pitotta (2011) ⁶	Vitamin D	No		<p>No pooled analyses. Lower quality studies tended to find positive associations between fibromyalgia and low vitamin D levels; studies with control groups found no significant associations; larger population-based studies had mixed findings</p>
Hsiao et al (2015) ²	Vitamin D	12	No	<p>Significantly higher odds of hypovitaminosis D among patients with chronic pain including fibromyalgia vs control group:</p> <ul style="list-style-type: none"> Crude OR=1.63 (95% CI, 1.20 to 2.23) Adjusted OR=1.41 (95% CI, 1.00 to 2.00)

CI: confidence interval; HR: hazard ratio; OR: odds ratio; RR: relative risk.

Subsection Summary: Mood Disorders, Fibromyalgia, or Unexplained Fatigue

Evidence from multiple systematic reviews and meta-analyses of observational studies have indicated an association between deficiency of nutrients (vitamin B₁₂, vitamin D, folate, magnesium, zinc) and different outcomes (depression, fibromyalgia). There is no evidence whether screening for these nutrient deficiencies results in improved health outcome compared with no screening.

Treatment of Mood Disorders, Fibromyalgia, or Unexplained Fatigue in Patients With Nutritional Deficiencies

Several systematic reviews and meta-analyses evaluating health outcomes in patients with depression treated with nutritional supplementation were identified, and they are described in Table 3. A limitation of all of the reviews is that they did not require patients to have an established deficiency of any nutrient. No systematic reviews or meta-analyses were identified on nutritional interventions in patients with fibromyalgia or unexplained fatigue.

Table 3. Systematic Reviews on Interventions for Patients With Mood Disorders, Fibromyalgia, and/or Unexplained Fatigue Diagnosed With Nutritional Deficiencies

Study	Intervention and Comparator	No. and Type of Studies	Patients Diagnosed With Nutritional Deficiencies	Key Findings
Depression				
Taylor et al (2003)⁸	Folic acid (alone or as adjunctive treatment) vs antidepressant medication	3 RCTs	No	Difference in HDRS scores significantly lower in patients taking folic acid plus antidepressants vs antidepressants alone (MD = -2.65; 95% CI, -4.93 to -0.038)
Gowda et al (2015)⁹	Vitamin D	9 RCTs	<ul style="list-style-type: none"> • No in overall analysis • Yes in subgroup analysis 	<ul style="list-style-type: none"> • No significant difference found in depression after supplementation with vitamin D vs placebo (SMD=0.28; 95% CI, -0.14 to 0.69) • No significant difference found in depression with vitamin D vs placebo in patients with baseline vitamin D >50 nmol/L or in patients with baseline vitamin D <50 nmol/L

CI: confidence interval; HDRS: Hamilton Depression Rating Scale; MD: mean difference; RCT: randomized controlled trial; SMD: standard mean difference.

Nowak et al (2016) conducted a single-center, double-blind, placebo-controlled trial to determine whether a single vitamin D dose would reduce fatigue after 30 days among 120 otherwise healthy persons with low serum 25-hydroxyvitamin D (25(OH)D) levels (mean age, 29 years; 53% women).¹⁰ The outcome was measured using the Fatigue Assessment Scale. The vitamin D group had a significantly greater decrease in mean (standard deviation [SD]) Fatigue Assessment Scale score (-3.3, SD=5.3) than the placebo group (-0.8, SD=5.3; p=0.01). Improvements were reported more frequently in the vitamin D group (42 [72%]) than in placebo group (31 [50%]; p=0.01; odds ratio, 2.63; 95% confidence interval for odds ratio, 1.23 to 5.62). Among all participants, improvement in Fatigue Assessment Scale correlated with the rise in 25(OH)D levels ($r=0.22$, $p=0.02$).

Subsection Summary: Treatment of Mood Disorders, Fibromyalgia, or Unexplained Fatigue in Patients With Nutritional Deficiencies

A systematic review and meta-analysis of randomized controlled trials have suggested that folate might have a role as a supplement to other therapies. However, it is unclear whether folate supplement would benefit both people with normal folate level and those with folate deficiency. A meta-analysis of randomized controlled trials has suggested no significant benefit of vitamin D supplementation vs placebo in the case of depression. There is no evidence whether screening for these nutrient deficiencies (vs no screening) would result in significant improvement in outcomes.

Panel Testing vs Testing for Individual Nutrients

There is no evidence on any indication to suggest that nutritional panel testing improves the net health outcome compared with testing for one or several individual nutrients. This includes patients with mood disorders, fibromyalgia, and/or unexplained fatigue, as well as healthy individuals seeking to optimize health and/or fitness. Moreover, with nutritional panel testing, there is a potential for incidental findings that could cause harm. Examples of potential harms include unnecessary confirmatory tests, unnecessary treatments provided for clinically insignificant conditions, and toxicity related to supplementation, or interactions between nutritional supplements and prescription medication.

Summary of Evidence

For individuals who have mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals who seek to optimize health and fitness who receive nutritional panel testing, the evidence includes several systematic reviews on the association between a single condition and a single nutrient and on the treatment of specific conditions with nutritional supplements. Relevant outcomes are symptoms, change in disease status, and functional outcomes. There was no evidence of associations between fibromyalgia or unexplained fatigue and nutrient deficiencies. Systematic reviews have found statistically significant associations between depression and levels of several nutrients; however, there is no evidence that nutrient supplementation for patients with depression improves health outcomes. Also, there is no direct evidence on the health benefits of nutritional panel testing for any condition, including testing healthy individuals, and no evidence that nutritional panel testing is superior to testing for individual nutrients for any condition. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Practice Guidelines and Position Statements

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force has not addressed nutritional panel testing. The Task Force has made several recommendations addressing screening for individual nutrients. The Task Force concluded that there is insufficient

evidence to recommend for or against screening for iron deficiency anemia in asymptomatic children and vitamin D deficiency in asymptomatic adults.^{11,12} Screening for iron deficiency anemia is recommended in pregnant women.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in November 2017 did not identify any ongoing or unpublished trials that would likely influence this review.

References

1. Genova Diagnostics. NutrEval FMV. 2015; <https://www.gdx.net/product/nutreval-fmv-nutritional-test-blood-urine>. Accessed November 21, 2017.
2. Swardfager W, Herrmann N, Mazereeuw G, et al. Zinc in depression: a meta-analysis. *Biol Psychiatry*. Dec 15 2013;74(12):872-878. PMID 23806573
3. Anglin RE, Samaan Z, Walter SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br J Psychiatry*. Feb 2013;202:100-107. PMID 23377209
4. Petridou ET, Kousoulis AA, Michelakos T, et al. Folate and B12 serum levels in association with depression in the aged: a systematic review and meta-analysis. *Aging Ment Health*. Jun 8 2015;1-9. PMID 26055921
5. Cheungpasitporn W, Thongprayoon C, Mao MA, et al. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. *Intern Med J*. Apr 2015;45(4):436-440. PMID 25827510
6. Daniel D, Pirodda MV. Fibromyalgia--should we be testing and treating for vitamin D deficiency? *Aust Fam Physician*. Sep 2011;40(9):712-716. PMID 21894281
7. Hsiao MY, Hung CY, Chang KV, et al. Is serum hypovitaminosis D associated with chronic widespread pain including fibromyalgia? A meta-analysis of observational studies. *Pain Physician*. Sep-Oct 2015;18(5):E877-887. PMID 26431141
8. Taylor MJ, Carney S, Geddes J, et al. Folate for depressive disorders. *Cochrane Database Syst Rev*. Jun 2003(2):CD003390. PMID 12804463
9. Gowda U, Mutowo MP, Smith BJ, et al. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. *Nutrition*. Mar 2015;31(3):421-429. PMID 25701329
10. Nowak A, Boesch L, Andres E, et al. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. *Medicine (Baltimore)*. Dec 2016;95(52):e5353. PMID 28033244
11. U.S. Preventive Services Task Force (USPSTF). Iron Deficiency Anemia: Screening. 2006; <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/iron-deficiency-anemia-screening>. Accessed November 7, 2017.
12. U.S. Preventive Services Task Force (USPSTF). Vitamin D Deficiency: Screening. 2014; <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/vitamin-d-deficiency-screening>. Accessed November 7, 2017.

Billing Coding/Physician Documentation Information

ICD-10 Codes

- F30.10-** Mood [affective] disorders code range
F39
M79.7 Fibromyalgia
R53.81- Other malaise and fatigue code range
R53.83

There are no specific codes for these panels of tests. Tests in the panel that have specific CPT codes would be reported using those codes such as folic acid (82746), magnesium (83735), manganese (83785), vitamin A (84590), zinc (84630). There are codes for testing multiple amino acids – 82128 for qualitative testing and 82136 for quantitative testing. The unlisted chemistry code 84999 would be used once for the other tests in the panel that do not have specific codes (or are used incorrectly with multiple units).

Additional Policy Key Words

N/A

Policy Implementation/Update Information

10/1/15 New Policy. Considered Investigational.

10/1/16 No policy statement changes.

10/1/17 No policy statement changes.

10/1/18 No policy statement changes.

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.